Mitsubishi Chemical Corporation: Patent Pertinent to Lithium-ion Secondary Battery for Vehicles Granted
Mitsubishi Chemical Corporation (“MCC”; HQ: Chiyoda-ku, Tokyo, President and Representative Director: Masayuki Waga) and MU Ionic Solutions Corporation (“MUIS”; HQ: Chiyoda-ku, Tokyo, President and Representative Director: Masaaki Tsuchiyama) announce the grant by the European Patent Office (“EPO”) of their jointly owned European patent pertaining to a lithium-ion secondary battery (European Patent Application Number: 06 83 2384.9; “the Patent”). The Patent, which relates to a lithium-ion secondary battery for vehicles, covers a combination of a nickel-containing positive electrode material, which is the standard choice in lithium-ion secondary batteries for vehicles, and an electrolyte comprising lithium difluorophosphate. The Patent, which has already been granted in Japan, US, China as well as South Korea, has now been additionally granted by the EPO with effect in Germany, where the demand for electric vehicles is increasing.
In recent years, nickel-containing positive electrode materials have been used in vehicle batteries because of their greater energy storage per unit volume when compared with other materials, and in order to achieve a higher capacity battery. The Patent offers a technology with extraordinary advantages for building batteries with a long life and high output, and in particular for a battery which is suited for quick recharging. This is a highly awaited development in terms of vehicle use, since this new technology, incorporating difluorophosphoric acid salt as the active component, is capable of improving the output characteristics of the batteries, in particular over known batteries using nickel-containing positive electrode materials, as well as the long-term retention of capacity, even after repeated charge/discharge cycles.
MCC and MUIS hold, apart from the Patent, a large number of further patents relating to materials for lithium-ion secondary batteries for vehicles. The prevalence of electric automobiles is expected to increase in the coming years across the globe, especially in Europe: this is driven not only as a solution to environmental challenges, such as the reduction of fossil fuel consumption and harmful gas emission, but also to allow a new society of next-generation mobility to be realized. MCC and MUIS will vigorously continue, in response to voracious demand, our activities as leading companies in the field of electrolytes for lithium-ion secondary batteries for vehicles, while promoting the healthy expansion of this market by means of appropriate use of intellectual property rights, thereby contributing to the realisation of a sustainable, next-generation society.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210201005012/en/
Contact information
For further information, please contact:
Public Relations and Investor Relations Office
Mitsubishi Chemical Holdings Corporation
Norihiko Urabe
Tel: [+81] (0)3-6748-7140
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Riyadh Declaration on the Future of Tourism Sets 50-Year Roadmap as UN Tourism 26th General Assembly Closes in Saudi Arabia11.11.2025 14:39:00 EET | Press release
The 26th session of the UN Tourism General Assembly concluded today with the adoption of the Riyadh Declaration on the Future of Tourism, a momentous step taken by member states toward enhanced cooperation over the next 50 years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111034542/en/ 26th UN Tourism General Assembly The Declaration reaffirms the Kingdom’s leadership in global tourism and its position at the heart of major, industry-changing decisions, as the ground-breaking Declaration is poised to play a central role in advancing the 2030 Agenda for Sustainable Development, emphasizing sustainability, digital innovation, AI integration, and inclusive tourism economies. The Riyadh Declaration on the Future of Tourism is a shared roadmap to guide the sector’s next half-century around sustainability, inclusion and AI-powered innovation.It underscores strengthening international cooperation, resilience, and the empower
Prokarium Appoints Ibs Mahmood as Chief Executive Officer11.11.2025 14:06:00 EET | Press release
Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, today announced the appointment of Ibs Mahmood as Chief Executive Officer (CEO). Ibs succeeds Kristen Albright, who will join the Board of Directors to continue shaping Prokarium’s strategic direction. Ibs brings 25 years as a biotechnology entrepreneur having founded and led multiple life science companies through clinical development, financing and strategic transactions, raising more than $300 million for his own ventures and over $2 billion for clients. He previously co-founded and led AMO Pharma, DrugDev and Induction Healthcare, and enjoyed senior roles at IQVIA, Abingworth, Shire Pharma and Investec. Ibs read medicine at the University of Oxford. “Ibs’ appointment marks an important step in Prokarium’s evolution. His unique blend of medical insight, entrepreneurial drive and industry experience will help us accelerate our mission to change the treatment paradigm in bladder canc
FDA Approves Promega OncoMate ® MSI Dx Analysis System as Companion Diagnostic for KEYTRUDA ® in Combination with LENVIMA ® In Advanced Endometrial Carcinoma11.11.2025 14:00:00 EET | Press release
The U.S. Food and Drug Administration (FDA) has approved the Promega OncoMate® MSI Dx Analysis System as a companion diagnostic designed to identify patients with microsatellite stable (MSS; defined as not MSI-high [not MSI-H]) endometrial carcinoma who may benefit from treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, plus LENVIMA® (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. This is the first Promega companion diagnostic to receive FDA approval. OncoMate® MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue. MSI status can be used to guide treatment decisions and support precision oncology strategies in endometrial carcinoma. “This approval underscores the critical role diagnostics play in accurately matching the right patients, at the right time with the right therapy,” says Alok Sharma, Global Clinical Market Director at Promega. “We are committed to delivering reliable
The International Swaps and Derivatives Association (ISDA) Endorses the Alignment of the Close-out Netting Regulation with International Standards11.11.2025 13:31:00 EET | Press release
The ISDA endorsed the Close-out Netting and related Collateral Arrangements Regulation adopted by the Capital Market Authority (CMA), which came into effect in July 2025, confirming its alignment with international standards. According to a statement published on ISDA's website, the Regulation adopted by the CMA was included within the scope of ISDA's legal opinions consistent with international derivatives agreements, signifying that the Kingdom of Saudi Arabia has become a jurisdiction supporting international netting legislation, strengthening the enforceability of such contracts at the international level. Mr. Raed Ibrahim Alhumaid, CMA Deputy of Market Institutions, explained that the Regulation approved four months ago was designed to regulate netting agreements and related financial collateral arrangements involving a Capital Market Institution. It aims to enhance the stability of the financial system and protect investors, contributing to the growth of investments in the capita
Picsart Expands Creative Platform With AI Products to Empower and Accelerate Vibe Design at Scale11.11.2025 12:00:00 EET | Press release
Picsart, the world’s leading digital creation platform with more than 2 billion downloads and used by 130 million monthly active users in more than 150 countries worldwide, today announced the expansion of its creative platform with AI products built to empower and accelerate vibe design at scale and simplify creative workflows. The announcement was made by Hovhannes Avoyan, Picsart co-founder and CEO, at Web Summit, one of the world’s largest technology conferences hosted annually in Lisbon, Portugal. Picsart enables a diverse set of creators to instantly bring their personal vision to life, offering more than 150 tools, millions of stickers, templates, UGC options, and premium stock content. Picsart is recognized for its engagement with the global Gen Z community, which represents more than 50% of its active user base. The company continues to grow organically alongside this group to provide real-world creative solutions, while equipping a global community of consumers, artists, entr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
